Timely administration of donor red
blood cells (RBCs)
is a crucial
and life-saving procedure to restore tissue oxygenation in patients
suffering from acute blood loss. However, important drawbacks of using
allogenic RBCs are their limited availability and portability, specific
storage requirements, short shelf life, or the need for blood type
matching. These limitations result in serious logistical challenges
that make the transfusion of donor RBCs difficult in extreme life-threatening
situations prior to hospital admission. Thus, the engineering of hemoglobin
(Hb) nanoparticles (Hb-NPs), which are free from the aforementioned
limitations, has emerged as a promising strategy to create RBC substitutes
to be used when donor blood is not available. Despite the tremendous
progress achieved in recent years, many challenges still need to be
overcome. For example, it is still difficult to create Hb-NPs with
a high Hb content while also preventing the autoxidation of Hb into
nonfunctional methemoglobin (metHb). Herein, the fabrication of small,
solid Hb-NPs with an antioxidant coating is reported. By desolvation
precipitation, Hb-NPs with an average hydrodynamic diameter of ∼250
nm and a polydispersity index of ∼0.2 are fabricated. A metal-phenolic
network (MPN) layer consisting of a phenolic ligand (i.e., tannic
acid) cross-linked through iron(III) ions is deposited onto the Hb-NPs
surface to render antioxidant protection. The resulting MPN-coated
Hb-NPs (MPN@Hb-NPs) maintain the ability of the encapsulated Hb to
reversibly bind and release oxygen. The antioxidant properties are
demonstrated, showing that MPN@Hb-NPs can effectively scavenge multiple
reactive oxygen and nitrogen species, both in solution and in the
presence of human RBCs and two relevant cell lines, namely, macrophages
and endothelial cells. Importantly, these outstanding antioxidant
properties resulting from the MPN translate into decreased metHb conversion.
Finally, the newly reported MPN@Hb-NPs are also biocompatible, as
shown by hemolysis rate and cell viability studies and can be used
to protect the cells from oxidative damage. All in all, we have identified
a novel strategy to minimize heme-mediated oxidative reactions that
could potentially bring this new generation of Hb-based oxygen carriers
a step closer to the clinic.